Brief: Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln

Novavax

26/02/2026 13:00

Feb 26 (Reuters) - Novavax Inc NVAX.O:

NOVAVAX OUTLOOK 2026 ADJUSTED TOTAL REVENUE $230 MILLION - $270 MILLION

NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&A EXPENSES NOW TARGETED TO BE $325 MILLION AND $225 MILLION FOR 2026 AND 2027, RESPECTIVELY

NOVAVAX Q4 EPS $0.11

NOVAVAX Q4 TOTAL REVENUE $147.1 MILLION

FY2026 REVENUE VIEW $377.0 MILLION -- LSEG IBES DATA

Q4 EARNINGS PER SHARE VIEW $-0.49, REVENUE VIEW $78.8 MILLION -- LSEG IBES DATA

NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&A EXPENSES FOR 2028 TARGETED TO BE AT $200 MILLION OR BELOW

Further company coverage: NVAX.O

 ((Reuters.Briefs@thomsonreuters.com;))